Chemo Stability Chart - AtoK

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART
DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special
(Storage Prior to Use, With: Stability Precautions/Notes
Manufacturer,
Preservative Status)
AGS-16C3F
1 1 1
30 mg 5.1 mL SWI 6 mg/mL discard unused ≥ 0.3 mg/mL complete - unopened vials
1
(Astellas) portion administration within may be kept at RT
2,3
(F)(PFL) swirl gently; do NOT 100 mL D5W 6 h RT of for up to 4h prior to
1 1 1
do not shake shake (PFL) reconstitution use if protected from
1 1
no preservative mix by gentle light
1
allow foam to clear inversion **(PFL)
1
before proceeding
record time of
reconstitution
Aldesleukin
4,5 4 4 4
22 million units 1.2 mL SWI 18 million unit/mL 48 h F 50 mL D5W 48 h F - do not use in-line
4,5 4,5
(1.3 mg) (1.1 mg/mL) filter
4
(Novartis) direct diluent against 30-70 mcg/mL - avoid bacteriostatic
(F)(PFL) side of vial during water for injection or
4 4
no preservative reconstitution Less than 30 mcg/mL: NS due to increased
4
dilute in D5W aggregation
4
do NOT shake containing human
5
albumin 0.1%
6,7 7
SC syringe 14 d F
**(PFL)
BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 1/53
This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy.
Activation Date: 2 March 2006
Revised Date: 1 July 2020
Manufacturer,
Alemtuzumab
9 10 11
30 mg/mL N/A filter NOT required discard unused SC syringe discard at the end of - do NOT shake
8 9
(Genzyme/Bayer) portion the day F, RT
9
(F)(PFL) 30 mg/mL
do not shake
9 9 9
no preservative 100 mL NS, D5W 8 h F, RT
11
**(PFL)
Amsacrine
12 12 12 12-14
75 mg/1.5 mL glass syringes 5 mg/mL 24 h RT 500 mL D5W 7 d F, 48 h RT - contains DMA***
(Erfa Canada) preferred during
12
(RT) reconstitution; (**PFL) (plastic or glass
12 12
no preservative max. time in plastic container)
12
syringe : 15 min
13.5 mL supplied
diluent (L-lactic
1
acid)
transfer 1.5mL from

ampoule into the
12
diluent vial
Arsenic trioxide
15 15
10 mg/10 mL N/A 1 mg/mL discard unused 100-250 mL NS, 48 h F, 24 h RT
15 15
(Lundbeck/Teva) portion D5W
(RT) (use filter needle to
15
no preservative withdraw from
ampoule)
Manufacturer,
Erwinia asparaginase
16 16 16 16
(asparaginase Erwinia 1-2 mL NS 10,000-5000 15 min RT syringe 4 h RT - contact with the
chrysanthemi) units/mL rubber stopper may
10,000 units do not shake; mix denature the
(CGF/Jazz) gently to minimize reconstituted drug,
(F) bubbles and contact creating filaments of
16 16
no preservative with stopper insoluble material; if
present, use 5
micron filter during
16
administration
- do not use sterile
water for
reconstitution as the
resulting product is
16
not isotonic
PEG-asparaginase -
see pegaspargase in
L-Z chart
(pegylated
asparaginase E. coli)
Atezolizumab
17 17 17 17
840 mg/14 mL N/A 60 mg/mL discard unused 250 mL NS 24 h F, 8 h RT - do NOT shake
17
1200 mg/20 mL portion
(Hoffman-La Roche) mix by gentle
17
(F)(PFL) inversion
do not shake
17
no preservative
Manufacturer,
Avelumab
18 18
200 mg/10 mL N/A 20 mg/mL discard unused 250 mL NS, complete - do NOT shake
19 18
(EMD) portion ½-NS administration within - use 0.2 micron in-
18
(F)(PFL) 24 h F, 8 h RT line filter to
18 18
no preservative if refrigerated, mix by gentle administer
18
bring vial to RT inversion if refrigerated, bring
18
prior to use bag to RT prior to
18
administration
Manufacturer,
azaCITIDine
20 20 20
100 mg 4 mL SWI 25 mg/mL 45 min RT, 8 h SC syringe 45 min RT (including - discard if contains
20 20
(Celgene) F preparation time), large particles
20 20
(RT) shake vigorously 8hF - re-suspend syringe
20
no preservative contents before
record time of refrigerate syringe injection by
reconstitution immediately after vigorously rolling
preparation if not to syringe between
20
be used within 45 palms
minutes of -if cold diluent
21
reconstitution reconstitution is used
to extend stability,
Refrigerated minimize exposure to
20
syringes : RT; ensure proper
 allow up to 30 min refrigeration of
prior to diluent, reconstituted
administration to vial, and final
reach a product
temperature of ~20-
25°C
discard syringe if
time elapsed at RT is
greater than 30 min
20 22,23 22,23
cold diluent 25 mg/mL 22 h F 22 h F
reconstitution:
4 mL SWI at 2-
22,23
8°C
Manufacturer,
azaCITIDine
24 24 24 24
100 mg 4 mL SWI 25 mg/mL 45 min RT, 8 h SC syringe 45 min RT (including - do not filter
24
(Dr. Reddy‘s) F preparation time), - discard if contains
24 24 24
(RT) shake vigorously 8hF large particles
24
no preservative - re-suspend syringe
refrigerate syringe contents before
immediately after injection by
preparation if not to vigorously rolling
be used within 45 syringe between
24
minutes of palms
24
reconstitution
Refrigerated
24
syringes :
 allow up to 30 min
prior to
administration to
reach a
temperature of
approximately 20-
25°C
 discard syringe if
time elapsed at RT
is greater than 30
min
Manufacturer,
BCG
8 25
(Tice substrain) 1 mL preservative- 1 to 8×10 2hF transfer from vial to use within 2 h F of - auxiliary info:
25 25 25,26 26
intravesical free NS CFU/vial 60 mL syringe, rinse reconstitution biohazard
8 25 25
50 mg = 1 to 8 x 10 **(PFL) vial with another 1 mL - do NOT filter
25 25
CFU allow to stand for a NS; add rinse to **(PFL) - do NOT shake
(Merck Canada) few minutes, then same 60 mL syringe
(F)(PFL) gently swirl to and qs to 50 mL with
25 25 25
no preservative suspend NS
record time of if a closed system

reconstitution transfer device is
used:
transfer from vial to
60 mL syringe and qs
to 50 mL with NS; do
25
NOT rinse vial
BCG
8 27
(Tice substrain) 1 mL preservative 1 to 8×10 2hF transfer from vial to use within 2 h F of - auxiliary info:
27 27 26,27 26
intravesical free NS CFU/vial 60 mL syringe and qs reconstitution biohazard
8 27 27 27
50 mg = 1 to 8 x 10 (PFL to 50 mL with NS - do NOT filter
27 27
CFU allow to stand for a **(PFL) - do NOT shake
(Merck USA) few minutes, then
(F)(PFL) gently swirl to
27 27
no preservative suspend
record time of
reconstitution
Manufacturer,
BCG
28 28
intravesical do NOT shake; roll 10.5 ± 8.7×108 2 h F, RT 50 mL NS 2 h F, RT after - auxiliary info:
28 28 19
81 mg to reconstitute CFU/vial reconstitution biohazard
(Sanofi Pasteur) (Connaught
28 28
(F)(PFL) 3 mL supplied strain) **(PFL)
28 28
preservative diluent
record time of
reconstitution
Belinostat
29 29 29 29
500 mg 9 mL SWI 50 mg/mL 12 h RT 250 mL NS complete - use 0.22 micron
(Spectrum) administration within inline filter to
29 29
(RT) 36 h RT administer
29
no preservative
Bendamustine
30 30
25 mg 25 mg vial: 5 mg/mL 30 minutes 0.2-0.6 mg/mL NS, complete
30 30
100 mg add 5 mL SWI D2.5-½NS administration within
31
(Lundbeck/Teva) 24 h F, 3 h RT
30
(RT,F)(PFL) 100 mg vial: 250* - 500 mL
30 30
no preservative add 20 mL SW
shake well;
dissolves completely
30
in 5 minutes
Manufacturer,
Bevacizumab
32 32 32 32
(AVASTIN®) N/A 25 mg/mL discard unused 1.4-16.5 mg/mL 48 h F, RT - do NOT shake
32
100 mg/4 mL portion
32
400 mg/16 mL in NS only
(Roche)
(F)(PFL)
do not shake
32
no preservative
Bevacizumab
33 33 33 33
(MVASI®) N/A 25 mg/mL discard unused 1.4-16.5 mg/mL 48 h F, RT - do NOT shake
33
100 mg/4 mL portion
33
(Amgen)
(F)(PFL)
do not shake
33
no preservative
Bevacizumab
34 34 34 34
(ZIRABEV®) N/A 25 mg/mL discard unused 1.4-16.5 mg/mL 48 h F, RT - do NOT shake
34
100 mg/4 mL portion
34
(Pfizer)
(F)(PFL)
do not shake
34
no preservative
Manufacturer,
Bleomycin
35 35 35 35
15 units 6 mL* NS 2.5 units/mL 48 h F 50 mL* NS 24 h RT
(NB: dose in units only)
(Fresenius Kabi)
(F)(PFL)
35
no preservative
Bleomycin
36 36 36 26,36
15 units 6 mL* NS, SWI 2.5 units/mL 48 h F, 24 h RT 50 mL* NS 4 h RT
(NB: dose in units only)
(Pfizer/Hospira)
(F)(PFL)
36
no preservative
Blinatumomab
37 37 37 37
38.5 mcg 3 mL SWI 12.5 mcg/mL 24 h F, 4 h RT 250 mL NS complete - use non-DEHP bag
(Amgen) administration within and IV administration
37 37
(F)(PFL) do NOT use add supplied IV 10 d F, 96 h RT set
do not shake supplied IV solution solution stabilizer to - use 0.2 or 0.22
37 37
no preservative stabilizer to NS bag and gently micron in-line filter
37
reconstitute vials mix to avoid - prime lines with
37
foaming blinatumomab
direct diluent against solution; do NOT use
side of vial during add reconstituted NS
37
reconstitution drug to bag following
addition of IV solution
37
gently swirl to avoid stabilizer
37
excess foaming
Manufacturer,
Bortezomib
38 38 39,40 38 39,40
SC injection 1.4 mL NS 2.5 mg/mL 2 d F, RT SC syringe 14 d F, 48 h RT - auxiliary info:
3.5 mg WARNING:
(Actavis) SUBCUTANEOUS
(RT)(PFL) use only. Fatal if
38
no preservative given by other
routes.
Bortezomib
38 38 39,40 38 39,40
3.5 mg 3.5 mL NS 1 mg/mL 2 d F, RT IV syringe 14 d F, 48 h RT - auxiliary info:
(Actavis) WARNING:
(RT)(PFL) INTRAVENOUS use
38
no preservative only. Fatal if given by
other routes.
Bortezomib
41 41 26,42 41 26,42
SC injection 1.4 mL NS 2.5 mg/mL 2d F, RT SC syringe 14 d F, 48 h RT - auxiliary info:
3.5 mg WARNING:
(Apotex) SUBCUTANEOUS
41
routes.
Bortezomib
41 41 26,42 41 26,42
3.5 mg 3.5 mL NS 1 mg/mL 2d F, RT IV syringe 14 d F, 48 h RT - auxiliary info:
(Apotex) WARNING:
41
other routes.
Manufacturer,
Bortezomib
43 43 39,40 43 39,40
3.5 mg WARNING:
(Janssen) SUBCUTANEOUS
43
routes.
Bortezomib
43 43 39,40 43 39,40
(Janssen) WARNING:
43
other routes.
Bortezomib
44 44 39,40 44 39,40
3.5 mg WARNING:
(Teva) SUBCUTANEOUS
44
routes.
Bortezomib
44 44 39,40 44 39,40
(Teva) WARNING:
44
other routes.
Manufacturer,
Brentuximab vedotin
45 45 45 45
50 mg 10.5 mL SWI 5 mg/mL 24 h F 0.4-1.8 mg/mL in NS, 24 h F - solution should be
(GMD/Seattle Genetics) D5W, Lactated clear to slightly
(F)(PFL) direct diluent against Ringer’s opalescent,
45
no preservative side of vial during colorless, and free of
45 45 45
reconstitution 100-250 mL visible particulates
45
do NOT shake
Busulfan
46
60 mg/10 mL N/A 6 mg/mL discard unused NS, D5W complete - contains DMA***
26,46
(PMS) portion (dilute to volume 10 administration within - always add
46
(F) times drug volume to 12 h F, 8 h RT busulfan to diluent to
46
no preservative achieve final mix; do not add
46
concentration of ~0.5 diluent to busulfan
46
mg/mL)
Busulfan
47
60 mg/10 mL N/A 6 mg/mL discard unused NS, D5W in NS: complete - contains DMA***
19,47
(SteriMax) portion (dilute to volume 10 administration within - always add
47
(F) times drug volume to 12 h F, 8 h RT busulfan to diluent to
47
no preservative achieve final mix; do not add
47
concentration of ~0.5 in D5W: complete diluent to busulfan
47
mg/mL) administration within
47
8 h RT
Manufacturer,
Cabazitaxel
48 48
45 mg/4.5 mL N/A 10 mg/mL 10 d F, RT 0.10-0.26 mg/mL NS, complete - use non-DEHP bag
48 48
60 mg/6 mL D5W administration within and tubing
48
(Sandoz) 48 h F, 8 h RT - use 0.22 micron in-
48 48
(RT) (e.g., 250 mL*) line filter
48
preservative - vials contain
48
overfill
Cabazitaxel
49 49
60 mg/1.5 mL supplied diluent: 10 mg/mL 1 h RT 0.10-0.26 mg/mL NS, complete - use non-DEHP bag
49 49
(sanofi-aventis) withdraw entire D5W administration within and tubing
49
(RT) contents of diluent 48 h F, 8 h RT - use 0.22 micron in-
49 49
no preservative vial and inject into (e.g., 250 mL*) line filter
the concentrate - concentrate and
49
vial diluent vials contain
49
overfill
slowly direct diluent - diluent contains
against inside of vial 13% (w/w) ethanol in
49 49
to limit foaming water
- discard if
mix by repeated crystallization
49
inversions for 45 occurs
49
sec
49
do NOT shake
49
let sit for 5 min
Manufacturer,
CARBOplatin
50 50 50
50 mg/5 mL N/A 10 mg/mL discard unused 0.5-10 mg/mL 24 h F, 8 h RT - do NOT use
50
150 mg/15 mL portion aluminum-containing
50
450 mg/45 mL NS, D5W needle, syringe, or
50
600 mg/60 mL tubing
(Accord)
(RT)(PFL)
50
no preservative
CARBOplatin
51 51 52
50 mg/5 mL N/A 10 mg/mL discard unused 0.3-10 mg/mL NS, 48 h F , 24 h RT - do NOT use
51 51
150 mg/15 mL portion D5W aluminum-containing
450 mg/45 mL needle, syringe or
51
600 mg/60 mL tubing
(Omega)
(RT)(PFL)
51
no preservative
CARBOplatin
53 53
50 mg/5 mL N/A 10 mg/mL discard unused 0.3-10 mg/mL NS, 48 h F - do NOT use
53 53
150 mg/15 mL portion D5W aluminum-containing
450 mg/45 mL needle, syringe, or
53
600 mg/60 mL tubing
(Pfizer/Hospira)
(RT)(PFL)
53
no preservative
Manufacturer,
CARBOplatin
54 55 54
50 mg/5 mL N/A 10 mg/mL discard unused 0.5-10 mg/mL 8 h RT - do NOT use
54
150 mg/15 mL portion RT aluminum-containing
54,56,57
450 mg/45 mL NS, D5W needle, syringe, or
54
(Teva/Novopharm) tubing
(RT)(PFL)
54
no preservative
Manufacturer,
Carfilzomib
58 58
10 mg 10 mg: 2 mg/mL 24 h F, 4 h RT 50-100 mL D5W complete - if a closed system
58 58
30 mg 5 mL SWI only administration within transfer device is not
60 mg 24 h F, 4 h RT after used for
58 58
(Amgen) 30 mg: do NOT dilute in NS reconstitution compounding, a 21
58
(F)(PFL) 15 mL SWI gauge (or larger
58
no preservative gauge) needle is
60 mg: recommended to
58
29 mL SWI prevent coring of the
58-60
vial stopper
direct diluent against
side of vial during
58
reconstitution
swirl gently; do NOT

58
shake
if foaming occurs,
allow to settle until
clear (about 5
58
minutes)
record time of
reconstitution
Manufacturer,
Carmustine
61 61 61
100 mg 3 mL diluent 3.3 mg/mL in 10% 24 h F, 8 h RT glass or polyolefin 24 h F: in glass or - do not use if
61 61 56 56
(Bristol Labs) (supplied) ethanol container polyolefin container product has oily
61
(F) droplets
61 61
no preservative diluent to reach RT, 500 mL NS or D5W use within 4 h of
61
then dissolve drug reconstitution RT
with 3 mL diluent;
61
add 27 mL SWI
record time of
reconstitution
Cemiplimab
62
250 mg/5 mL N/A 50 mg/mL discard unused 1-20 mg/mL complete - administer using
26,62 62 62
350 mg/7 mL portion NS, D5W administration within 0.2-5 micron filter
62
(sanofi) 24 h F, 8 h RT
63
(F)(PFL) 50-100* mL
do not shake
62
no preservative mix by gentle
inversion
Cetuximab
64 64 64 64
100 mg/50 mL N/A 2 mg/mL 12 h F, 8 h RT syringe 12 h F, 8 h RT - administer using
64
200 mg/100 mL 0.22 micron filter
(Imclone/Lilly)
(F) evacuated container
64
do not shake or bag
64
no preservative
Manufacturer,
CISplatin
65 65
10 mg/10 mL N/A 1 mg/mL discard unused Less than or equal to 24 h RT - do NOT use
26
50 mg/50 mL portion 60 mg: aluminum-containing
100 mg/100mL 100 mL* NS needle, syringe or
65
(Accord) tubing
(RT)(PFL) Greater than 60 mg: - suggested dose
65
no preservative 250 mL* NS limits relate to the
physical limitations of
2 L of D5 in one-half the bag size and
or one-third NS added drug volume;
containing 37.5 g of it is not a
65
mannitol concentration-
dependent property
of the drug
CISplatin
66 66
26
100 mg/100mL portion 60 mg: aluminum-containing
(Pfizer/Hospira) 100 mL* NS needle, syringe or
66
(RT)(PFL) tubing
66
no preservative Greater than 60 mg: - suggested dose
250 mL* NS limits relate to the
66
dependent property
of the drug
Manufacturer,
CISplatin
67 67,68 67
10 mg/10 mL N/A 1 mg/mL 48 h RT Less than or equal to 24 h RT - do NOT use
50 mg/50 mL 60 mg: aluminum-containing
100 mg/100mL 100 mL NS* needle, syringe or
67
(Sandoz) tubing
67
no preservative 250 mL NS* limits relate to the
NS, 0.45% sodium the bag size and
chloride with or added drug volume;
69
without mannitol it is not a
concentration-
2 L of D5 in one-half dependent property
or one-third NS of the drug
containing 37.5 g of
67
mannitol
CISplatin
70 70
19
50 mg/50 mL portion 60 mg: aluminum-containing
100 mg/100mL 100 mL* NS needle, syringe or
70
(Teva) tubing
70
no preservative 250 mL* NS limits relate to the
70
dependent property
of the drug
Manufacturer,
Cladribine
71 72
10 mg/10 mL N/A 1 mg/mL discard unused SC syringe discard end of
71 13,71,73
(Fresenius Kabi) potion day
(F)(PFL)
71
no preservative
500 mL NS only 24 h RT
do NOT use D5W
71
Cassette: at least 7 days
qs to 100 mL with
bacteriostatic NS
only via SIMS
DELTEC INC.
MEDICATION
71
CASSETTES® filter
drug and diluent
through 0.22 micron
filter as each solution
is being introduced
into the cassette
Manufacturer,
Cyclophosphamide
74 74 75-77
200 mg 200 mg : 20 mg/mL 48 h F, 24 h 100-500 mL* NS, 36 h F, 24 h RT - suggested dose
26,74 74
500 mg 10 mL NS RT D5W, D5NS limits relate to the
1000 mg physical limitations of
74
2000 mg 500 mg : Less than or equal to the bag size and
(Baxter) 25 mL NS 1 g: 100 mL* added drug volume;
(RT)(PFL) it is not a
74 74
no preservative 1000 mg : Greater than 1 g: concentration-
50 mL NS 250 mL* dependent property
of the drug
74
2000 mg : high dose in BMT:
100 mL NS may need 500 mL*
Cytarabine
78 78
1000 mg/10mL N/A 100 mg/mL discard unused 0.1-37.5 mg/mL NS, 10 d F, 48 h RT
26,78 78
2000 mg/20mL portion D5W, SWI
(Pfizer/Hospira) **(PFL)
(RT)(PFL) 100 mL* NS, D5W,
78
no preservative SWI
Manufacturer,
Cytarabine
78
IT injection N/A 100 mg/mL use within 4 h of diluents containing use within 4 h of - auxiliary info: IT
26 26
1000 mg/10mL initial vial preservatives should initial vial puncture injection
26
2000 mg/20mL record time of puncture NOT be used for - label to include
(Pfizer/Hospira) puncture intrathecal **(PFL) route in full (i.e.,
78
(RT)(PFL) administration INTRATHECAL
78
no preservative injection) attached to
qs to 6 mL with both syringe and
81
preservative free outer ziplock bag
79,80
NS
Cytarabine
78 78
SC injection N/A 100 mg/mL discard unused syringe 10 d F, 48 h RT
26,78
1000 mg/10mL portion
2000 mg/20mL **(PFL)
(Pfizer/Hospira)
(RT)(PFL)
82
no preservative
Cytarabine
83 83
1000 mg/10mL N/A 100 mg/mL discard unused 0.1-37.5 mg/mL NS, 10 d F, 48 h RT
26,83 83
2000 mg/20mL portion D5W, SWI
(PMS) **(PFL)
(RT)(PFL) 100 mL* NS, D5W,
83
no preservative SWI
Manufacturer,
Cytarabine
83
IT injection N/A 100 mg/mL use within 4 h of diluents containing use within 4 h of - auxiliary info: IT
26 26
1000 mg/10mL initial vial preservatives should initial vial puncture injection
26
2000 mg/20mL record time of puncture NOT be used for - label to include
(PMS) puncture intrathecal **(PFL) route in full (i.e.,
83
(RT)(PFL) administration INTRATHECAL
83
no preservative injection) attached to
qs to 6 mL with both syringe and
81
preservative free outer ziplock bag
79,80
NS
Cytarabine
83 83
SC injection N/A 100 mg/mL discard unused syringe 10 d F, 48 h RT
26,83
1000 mg/10mL portion
2000 mg/20mL **(PFL)
(PMS)
(RT)(PFL)
83
no preservative
Dacarbazine
84 84 84
100 mg 100 mg: 10 mg/mL 72 h F, 8 h RT 250-1000 mL* NS, 24 h F, 8 h RT - protect container
84
200 mg 9.9 mL SWI D5W from light during
56,84
(Abraxis) **(PFL) storage and
85
(F)(PFL) 200 mg: administration
84 84
no preservative 19.7 mL SWI - overfill unknown
Manufacturer,
Dacarbazine
86 86 13,86 86
200 mg 200 mg: 10 mg/mL 8 h RT, 48 h F 0.19–3.0 mg/mL 24 h F - protect container
86
600 mg 19.7 mL SWI from light during
87 85
(Hospira) (PFL) 250-1000 mL* NS, **(PFL) storage and
85
(F)(PFL) 600 mg: D5W administration
86 86 87,88
no preservative 59.1 mL SWI - no overfill
Dacarbazine
89 89 89 89
600 mg 59.1 mL SWI 10 mg/mL 24 h F, 8 h RT 0.19-3.0 mg/mL in 24 h F - protect container
89
(Pfizer) D5W or NS from light during
85
(F)(PFL) **(PFL) storage and
89 85
no preservative administration
DACTINomycin
90
0.5 mg 1.1 mL SWI 0.5 mg/mL discard unused syringe use within 4 h of - drug loss reported
90 90 68 68
(GMD Pharma for (preservative-free) (500 mcg/mL) portion initial vial puncture with some cellulose
Recordati) ester membrane in-
90
(RT)(PFL) do NOT use SWI 10 mcg/mL or line filters
90 90
no preservative with preservative greater
(may form
90 90,91
precipitate) NS, D5W
Manufacturer,
Daratumumab
92
100 mg/5mL N/A 20 mg/mL discard unused 500-1000 mL NS 24 h F, followed by - administer with a
92
400 mg/20mL portion 15 h infusion (total 39 0.22 or 0.2 micron in-
92 92
(Janssen) dilute to final volume h) line filter
(F)(PFL) by withdrawing - discard if visible
do not shake volume from bag allow bag to come to particles are
92 92
no preservative equal to volume of room temperature, observed
92
drug to be added then use - complete infusion
92 92
immediately within 15 hours
mix by gentle
92
inversion **(PFL)
DAUNOrubicin
93 93,96 95 93
20 mg 4 mL SWI 5 mg/mL 48 h F, 24 h RT 100-250 mL in 48 h F, 24 h RT
93
(Erfa Canada Inc.) isotonic solution e.g.,
94 93
(RT)(PFL) NS
95
no preservative
95
no data for D5W
DAUNOrubicin
97 97 97 97
20 mg 4 mL SWI 5 mg/mL 48 h F, 24 h RT 100-250 mL 48 h F, 24 h RT
56
(Teva/Novopharm) NS, D5W
97 97
(RT)(PFL) **(PFL) **(PFL)
97
no preservative
Manufacturer,
Degarelix
98 98 98 98
80 mg 80 mg: 20 mg/mL 2 h RT SC syringe 2 h RT
120 mg 4.2 mL SWI
98
(Ferring) (supplied diluent)
(RT)
98
do not shake
99 98
no preservative 120 mg: 40 mg/mL
3 mL SWI (supplied
98
diluent)
swirl gently; avoid

shaking to prevent
98
foam formation
reconstitution may
98
take up to 15 min
Manufacturer,
Denosumab
100 100
(XGEVA®) N/A 71 mg/mL discard unused SC syringe use within 4 h of - not interchangeable
68,100 68 100
120 mg/1.7 mL portion initial puncture with PROLIA
(Amgen) - do not use if
(F)(PFL) solution is cloudy;
do not shake trace amounts of
100
no preservative translucent to white
proteinaceous
particles are
100
acceptable
- avoid vigorous
100
shaking
- bring to room
temperature 15-30
minutes prior to
100
administration
Dexrazoxane
101 101
250 mg 250 mg: 10 mg/mL 3 h F, 30 min MUST BE FURTHER 4 h F, 1 h RT
101 102
500 mg 25 mL SWI RT DILUTED With
(Pfizer) Lactated Ringers
(RT) 500 mg: Injection to 1.3 – 3.0
101 101 101
no preservative 50 mL SWI mg/mL
Manufacturer,
Dinutuximab
103 103 103
17.5 mg/5 mL N/A 3.5 mg/mL discard unused 100 mL NS initiate infusion within - do NOT shake
26
(Unither/United portion 4 h of dilution;
Therapies) mix by gentle refrigerate bag if not
103 103
(F)(PFL) inversion hung immediately
do not shake
103
no preservative complete
administration within
103
24 h of dilution
Manufacturer,
DOCEtaxel
104 104
20 mg/2 mL N/A 10 mg/mL 20mg/2 mL vial: 0.3-0.74 mg/mL complete - use non-DEHP bag
80 mg/8 mL discard unused administration within and IV administration
19,104 104 104
160 mg/16 mL portion 250 mL* NS, D5W 14 d F, 48 h set
19,105,106
(Pfizer/Hospira) RT
(F, RT)(PFL)
104
preservative 80 mg/8 mL or
160 mg/16 mL
104
vial (maximum
number of
punctures: up to 3
doses can be
removed when a
venting needle is
also inserted, i.e.,
6 punctures
106
total)
19,104
14 d F
104
**(PFL)
DOCEtaxel
107 19,108 107
20 mg/2 mL N/A 10 mg/mL 14 d F, RT 0.3-0.74 mg/mL complete - use non-DEHP bag
80 mg/8 mL administration within and IV administration
107 107,109 107
160 mg/16 mL 250 mL* NS, D5W 24 h F, 4 h RT set
(Sandoz)
(F,RT)(PFL)
107
preservative
Manufacturer,
DOCEtaxel
110 19,110,111 110
20 mg/0.5 mL supplied diluent : 10 mg/mL 14 d F, RT 0.3-0.74 mg/mL complete - use non-DEHP
80 mg/2 mL - if vials were administration within bag and IV
110 110 110
(sanofi-aventis) refrigerated, allow to 250 mL NS, D5W 4 h F, administration set
19,111
(F, RT)(PFL) warm for 5 min at 48 h RT
110
no preservative RT. Withdraw entire
contents of the
diluent and inject the
entire contents of
the syringe into the
corresponding
concentrate vial. Mix
by repeated
inversions for 45
110
sec
110
do NOT shake
Let sit for 5

110
minutes
DOXOrubicin
112 112 112
10 mg/5 mL N/A 2 mg/mL 8h syringe 24 h F, RT from initial - for ULYEPOCHR
112
20 mg/10 mL vial puncture protocol, see entry
50 mg/25 mL for EPOCHR
200 mg/100 mL (3-in-1solution
(Accord) containing
(F)(PFL) etoposide,
112
no preservative DOXOrubicin,
vinCRIStine)
Manufacturer,
DOXOrubicin
113 113 13,114
10 mg 10 mg: 2 mg/mL 48 h F, 24 h syringe 48 h F, 24 h RT - for ULYEPOCHR
13,113
50 mg 5 mL NS, SWI, RT protocol, see entry
113
150 mg D5W for EPOCHR
(Hospira) (3-in-1solution
(RT)(PFL) 50 mg: containing
113
no preservative 25 mL NS, SWI, etoposide,
113
D5W DOXOrubicin,
vinCRIStine)
150 mg:
75 mL NS, SWI,
113
D5W
(NS reconstitution
113
takes longer)
DOXOrubicin
115 115 115 115
10 mg/5 mL N/A 2 mg/mL 8h syringe 48 h F, 24 h RT - for ULYEPOCHR
20 mg/10 mL from initial vial protocol, see entry
50 mg/25 mL record time of puncture for EPOCHR
200 mg/100 mL puncture (3-in-1solution
(Teva/Novopharm) containing
(F)(PFL) etoposide,
115
no preservative DOXOrubicin,
vinCRIStine)
Manufacturer,
DOXOrubicin
116 116 116
10 mg/5 mL N/A 2 mg/mL discard unused syringe 48 h F, 24 h RT - for ULYEPOCHR
68,116
50 mg/25 mL portion protocol, see entry
200 mg/100 mL for EPOCHR
(Pfizer) (3-in-1solution
(F) containing
116
no preservative etoposide,
DOXOrubicin,
vinCRIStine)
DOXOrubicin
117 117 117
Pegylated Liposomal N/A 2 mg/mL discard unused Less than 90 mg: 250 24 h F - do not filter
117 117
20 mg/10 mL portion mL D5W only
(Janssen)
(F) Greater than or equal
117
no preservative to 90 mg: 500mL
117
D5W only
Durvalumab
118 118 118
120 mg/2.4 mL N/A 50 mg/mL discard unused 1-15 mg/mL NS, 24 h F, 12 h RT - do NOT shake
118 118
500 mg/10 mL portion D5W - use 0.2-0.22 micron
(AstraZeneca) in-line filter to
118
(F)(PFL) (e.g., 100 mL* NS, administer
do not shake D5W)
118
no preservative
mix by gentle
118
inversion
Manufacturer,
Epirubicin
119 119 119
10 mg/5 mL N/A 2 mg/mL 8 h F, RT syringe 48 h F, 24 h RT
20 mg/10 mL from initial vial
119
50 mg/25 mL puncture
150 mg/75 mL
200 mg/100 mL
(Teva/Novopharm)
(F)(PFL)
119
no preservative
Epirubicin
120 120 120
10 mg/5 mL N/A 2 mg/mL 8h syringe 48 h F, 24 h RT
50 mg/25 mL from initial vial
120
200 mg/100 mL record time of puncture
(Fresenius Kabi) puncture
(F)(PFL)
120 19,120
no preservative 100 mL* NS, D5W 2 d F, RT
Epirubicin
121 121 121
10 mg/5 mL N/A 2 mg/mL 8h syringe 48 h F, 24 h RT from
121
50 mg/25 mL initial vial puncture
200 mg/100 mL record time of
(Pfizer) puncture
56 122
(F)(PFL) 100 mL* NS, D5W 2 d F, RT
121
no preservative
Manufacturer,
EPOCHR
(ULYEPOCHR protocol) see brand specific see brand specific see brand etoposide dose etoposide - final product is a
(RT) entries for: entries for: specific entries ≤125 mg/24 h: concentration 3-in-1 solution
19,123-126
no preservative DOXOrubicin as DOXOrubicin, for: DOXOrubicin, in 500 mL NS ≤0.25 mg/mL: containing
applicable etoposide, etoposide, complete etoposide,
vinCRIStine vinCRIStine etoposide dose administration within DOXOrubicin,
>125 mg/24 h: 72 h RT vinCRIStine (refer to
in 1000 mL NS ULYEPOCHR
precipitation occurs protocol)
at etoposide - use non-DEHP bag
concentrations and tubing only
>0.25 mg/mL - use 0.22 micron
inline filter
eriBULin
127 127 127
1 mg/2 mL N/A 0.5 mg/mL discard unused IV syringe 24 h F, 6 h RT - do not administer
19,127
(Eisai Limited) portion through dextrose
127 127
(RT)(PFL) containing lines
19
no preservative - vials contain
dehydrated alcohol
127
USP (5% v/v)
Manufacturer,
Etoposide
128 128
100 mg/5 mL N/A 20 mg/mL 14 d RT 0.2-0.4 mg/mL NS, 0.2 mg/mL: - use non-DEHP bag
128 128
200 mg/10 mL D5W 7 d F, RT and tubing only
500 mg/25 mL - use 0.22 micron in-
129
1000 mg/50 mL 500 mL* NS, D5W 0.4 mg/mL: line filter
128
(Sandoz) 12 h F, RT - for ULYEPOCHR
(RT)(PFL) protocol, see entry
128
preservative for EPOCHR
(3-in-1solution
containing
etoposide,
DOXOrubicin,
vinCRIStine)
Manufacturer,
Etoposide
130
100 mg/5 mL N/A 20 mg/mL discard unused NS 0.2-0.3 mg/mL: - use non-DEHP bag
130 131 131,132
200 mg/10 mL portion 7 d F, 2 d RT and tubing only
500 mg/25 mL Stability is - use 0.22 micron in-
129
1000 mg/50 mL concentration 0.4-0.5 mg/mL: line filter
131 131
(Teva/Novopharm) dependent 1 d F, 1d RT - for ULYEPOCHR
(RT)(PFL) protocol, see entry
130
no preservative 0.6-9.0mg/mL: for EPOCHR
generally unstable (3-in-1solution
containing
9.5 mg/mL: etoposide,
131 131
2 d F, 1d RT DOXOrubicin,
vinCRIStine)
10-12 mg/mL:
131 131,132
7 d F, 2 d RT
130 130,133
D5W 4 h RT
Etoposide phosphate
134,137 19,134,137 134,137
(ETOPOPHOS®) 5 mL NS, D5W, 20 mg/mL 48 h F , 24 500 mL* NS, 24 h F, RT
134,137 134,137 134,137
100 mg SWI, BWI h RT , D5W
(Xediton/Cheplapharm)
(F)(PFL) (do not dilute to less
134-136 134,137 134,137
no preservative 10 mL NS, D5W, 10 mg/mL than 0.1 mg/mL)
134,137
SWI, BWI
Manufacturer,
Filgrastim
138 138 19,139
(NEUPOGEN®) N/A 300 mcg/mL discard unused SC syringe 14 d F - albumin is added to
19
300 mcg/1 mL portion D5W to prevent
480 mcg/1.6 mL filgrastim adsorption
19,139 138
(Amgen) 50-100 mL D5W 7 d F, 48 h RT to plastic
140
(F)(PFL) only - incompatible with
138,140
do not shake saline
138
no preservative in PVC, polyolefin, or - do NOT dilute to
138
glass less than 5
138
mcg/mL
(for filgrastim
concentrations of 5-
15 mcg/mL in D5W,
add albumin 2
138
mg/mL)
Fludarabine
141 141 13,122 13,122
50 mg 2 mL SWI 25 mg/mL 48 h F, RT dilute to maximum of 48 h F, RT
141,142
(Berlex) 1 mg/mL
(F)
141
no preservative 50-100 mL NS,
141
D5W
Fludarabine
143 143
50 mg N/A 25 mg/mL discard unused dilute to maximum of 48 h F, 24 h RT
143 143
(Teva/Novopharm) portion 1 mg/mL
(F)
143
no preservative (e.g., 50-100 mL* NS,
D5W)
Manufacturer,
Fluorouracil
144 19,145 144 19,145
5000 mg/100 mL N/A 50 mg/mL 48 h RT syringe 48 h RT
(Accord)
(RT)(PFL)
144 145 19,145
no preservative 0.5-10 mg/mL 48 h RT
(e.g., 50-1000 mL*

D5W)
CIVI: ambulatory complete within 8

146 145
pump d
Fluorouracil
147 147 147 26,147
(Pfizer/Hospira)
(RT)(PFL)
147 148 147
no preservative 0.5-10 mg/mL 24 h RT
(e.g., 50-1000 mL*

D5W)
CIVI: ambulatory complete within

146 13,56,149,150
pump 8d
Manufacturer,
Fluorouracil
151 26,152 26,151
5000 mg/100 mL
(Sandoz)
152 26,152
(RT)(PFL) 0.35-15 mg/mL 48 h RT
151
no preservative
151
(300-500 mL D5W)
CIVI: ambulatory complete within

146 13,56,149,150
pump 8d
Gemcitabine
153 153 153 153
200 mg 200 mg: 38 mg/mL 24 h RT syringe 24 h RT
153
1000 mg 5 mL NS
2000 mg
153 19,154,155
(Accord) 1000 mg: 0.1-38 mg/mL NS 48 h RT
153
(RT) 25 mL NS
153
no preservative
2000 mg:
153
50 mL NS
Gemcitabine
157 157 156
200 mg/5.3 mL N/A 38 mg/mL discard unused syringe 24 h RT
156
1000 mg/26.3 mL portion
2000 mg/52.6 mL
(Pfizer/Hospira) 0.1–38 mg/mL NS,
156
(F) D5W
156
no preservative
Manufacturer,
Gemcitabine
158 158 158
(NOTE: concentration) N/A 40 mg/mL discard unused syringe 24 h RT CAUTION:
158
200 mg/5 mL portion alternative
1000 mg/25 mL concentration
2000 mg/50 mL 0.1–40 mg/mL NS,
(Sandoz) D5W
158
(F)
158
no preservative
IDArubicin
159 159 159
5 mg 5 mg: 1 mg/mL 48 h F, syringe 48 h F, 24 h RT - avoid alkaline
159 159 159
10mg 5 mL SWI 24 h RT solutions
(Pfizer)
159
(RT)(PFL) 10 mg: **(PFL)
159 159
no preservative 10 mL SWI
vial contents under

159
negative pressure
do NOT use BWI to

159
reconstitute
IDArubicin PFS
159 159
5 mg/5 mL N/A 1 mg/mL 48 h F, 24 h RT, syringe 4 h from initial - avoid alkaline
19 159
10 mg/10 mL puncture solutions
159
20 mg/20 mL **(PFL)
(Pfizer)
(F)(PFL)
159
no preservative
Manufacturer,
IDArubicin
160 160
5 mg/5 mL N/A 1 mg/mL discard unused syringe 4 h from initial - avoid alkaline
160 19 160
10 mg/10 mL solution puncture solutions
20 mg/20 mL
(Fresenius Kabi)
(F)(PFL)
160
no preservative
Ifosfamide
161 161 161
1000 mg 1000 mg: 50 mg/mL 48 h F, 24 h 0.6–20 mg/mL 72 h F, 24 h RT
161 19,161
3000 mg 20 mL SWI RT
(Baxter) 500–1000 mL* NS, 24 h F, RT when
56
(RT) 3000 mg: D5W, Lactated mixed with mesna
161 161 161
no preservative 60 mL SWI Ringer’s
shake well
Ifosfamide
162 162 162
1000 mg 1000 mg: 50 mg/mL 48 h F, 24 h 0.6-20 mg/mL 72 h F, 24 h RT
162 19,162
3000 mg 20 mL SWI RT
(Fresenius Kabi) 24 h F, RT when
56
(RT) 3000 mg: 500-1000 mL* NS mixed with mesna
162 162
no preservative 60 mL SWI D5W, Lactated
162
Ringer’s
shake well
Manufacturer,
Iniparib
163 163
100 mg/10 mL N/A 10 mg/mL discard unused 250 mL NS, D5W 24 h RT - *may also use
163
(sanofi-aventis) portion empty IV bag and qs
(F) dilute to 250 mL final to final volume of
163
no preservative volume by 250 mL with NS,
163
withdrawing volume D5W
from bag equal to
volume of drug to be
163
added*
Inotuzumab
164 164 164 164
ozogamicin 4 mL SWI 0.25 mg/mL 4hF 0.01- 0.1 mg/mL complete - do NOT shake
164
0.9 mg NS administration within - protect container
(Pfizer) gently swirl vial to record time of dilute dose within 8 h of reconstitution from UV and
164 164 164
(F)(PFL) mix reconstitution 4 hours of (50 mL* NS) F, RT fluorescent light
164 164
no preservative reconstitution during storage and
164 164,165
(PFL) administration
protect from light mix by gentle - protect
164
if not used inversion if refrigerated, bring administration line
165
immediately bag to RT over 1 h from light ONLY if
prior to hang time will be
164 164,165
administration longer than 1 h
Manufacturer,
Interferon Alfa -2b
166 166 19
10 million units/1 mL N/A 10 million 7dF syringe 7dF - vials can be kept at
166
(Merck) units/mL RT for up to 7 days
(F) before use; discard if
166,167 166
preservative final concentration 24 h F, RT not used within this
166 166
≥ 0.3 million IU/mL time
166
50 mL NS
Interferon Alfa -2b

19,166 166 19,167
18 million units/3 mL N/A 6 million 14 d F syringe 14 d F - vials can be kept at
166
166,167 166
166 166
166
50 mL NS
Interferon Alfa -2b

19,166 166 19,167
25 million units/2.5 mL N/A 10 million 14 d F syringe 14 d F - vials can be kept at
166
166,167 166
166 166
166
50 mL NS
Manufacturer,
Interferon Alfa -2b
166 166 19,167
10 million units 1 mL supplied 10 million 24 h F syringe 24 h F - after reconstitution,
166 166
(Merck) diluent (SWI) units/mL provides an isotonic
(F) solution which may
no preservative (unless do NOT shake; roll be used for
166 167
reconstituted with to reconstitute final concentration 24 h F, RT intralesional
166 166 166
BWI) ≥ 0.1 million IU/mL injection
- non-reconstituted
166
100 mL NS vials can be kept at
RT for up to 4 weeks
before use; discard if
166 19,166 166 19,166
1 mL BWI 14 d F syringe 14 d F not reconstituted for
use within this
166
do NOT shake; roll time
166 167
to reconstitute final concentration 24 h F, RT
166
≥ 0.1 million IU/mL
166
100 mL NS
Manufacturer,
Ipilimumab
168 168 168 168
50 mg/10 mL N/A 5 mg/mL 24 h F,RT 1- 4 mg/mL NS, 24 h F,RT - do NOT shake
168
200 mg/40 mL D5W - administer with 0.2
168
(BMS Canada) or 0.22 in-line filter
(F)(PFL) OR - vials may contain
168
no preservative undiluted in empty translucent-to-white
viaflex bag or glass amorphous
168
bottle particles
- discard if cloudy or
(allow vials to stand at has pronounced
RT for ~5 min prior to colour change
withdrawal of (should be clear to
168 168
contents) pale yellow)
Irinotecan
169
40 mg/2 mL N/A 20 mg/mL discard unused 0.12–3 mg/mL D5W 48 h F, 24 h RT
169 169
100 mg/5 mL portion (preferred), NS
169
500 mg/25 mL **(PFL)
56
(Accord) 500* mL
(RT)(PFL)
169
no preservative
Irinotecan
170,171
40 mg/2 mL N/A 20 mg/mL discard unused 0.12-3 mg/mL 14 d F, 48 h
170,171 26,170,171
100 mg/5 mL portion D5W (preferred), RT
170,171
300 mg/15 mL NS
170,171
500 mg/25 mL **(PFL)
56
(Pfizer/Hospira) 500* mL
(RT)(PFL)
170,171
no preservative
Manufacturer,
Irinotecan Liposome
172 172
43 mg/10 mL N/A 4.3 mg/mL discard unused to a final volume of 24 h F, 4 h RT - do not use in-line
172 172
(Servier) portion 500 mL with NS, filter
172
(F)(PFL) D5W **(PFL) - expressed as
172
no preservative irinotecan free base
mix by gentle (allow product to
172
inversion come to RT prior to
administration if
172
stored in F)
Ixabepilone
173 173 173
15 mg 15 mg: 2 mg/mL 1 h RT 0.2-0.6 mg/mL in 6 h RT - use 0.2-1.2 micron
173
(contains 16 mg) 8 mL supplied Lactated Ringer’s in-line filter
173
45 mg diluent Injection USP (use - use non-DEHP bag
(contains 47 mg) non-DEHP infusion and administration
173 173
(BMS) 45 mg: container) set
(F)(PFL) 23.5 mL supplied
173 173
no preservative diluent
* Suggested volume based on usual dose range and any concentration range of stability data
** Protect from light means minimizing exposure to direct sunlight over a storage period. More specific information on protection from light (eg, protecting container and tubing during
administration) will be indicated in the Special Precautions/Notes column.
*** Contains DMA (N,N dimethylacetamide). Product may be incompatible with closed system transfer devices such as ChemoLock.
Centres are not to change content locally. All suggestions for change are to be forwarded to the Cancer Drug Manual editor.
Explanatory Notes:
Stability data assumes products prepared using standard aseptic technique in biological safety cabinet at low risk for contamination according to
174,175
the classification outlined in USP 797.
Vial stability: Stability of solution after first puncture or reconstituted solution.
Storage temperature: If information states same stability with refrigerator and room temperature storage, then fridge stability is bolded as preferred
(ie, to minimize growth of micro-organisms).
Discard unused portion: Unused portion from single use vials should be discarded at the end of the day.
“overfill known” is stated if the manufacturer states overfill that is present is within acceptable limits.
“Complete administration within __” is stated if the manufacturer specifies that the infusion must be completed in a specific time frame following
preparation, usually including entire time required for preparation (from first puncture), storage, and administration of infusion.
Abbreviations:
BWI = bacteriostatic water for injection

CIVI: ambulatory pump = Continuous Intravenous Infusion (e.g., elastomeric infusor)
D5W = dextrose 5% in water
DMA = N,N dimethylacetamide
F = refrigerate
Non-DEHP = not containing Di(2-ethylhexyl) phthalate (DEHP)
NS = normal saline
PFL = protect from light
RT = room temperature
SWI = sterile water for injection
References:
1. Agensys. Pharmacy Guide Protocol AGS-16C3F-15-3: A multi-center, open label, randomized phase 2 study of AGS-16C3F vs. axitinib in metastatic renal cell carcinoma. Santa
Monica, California; 8 June 2016 - version 2.0.
2. BC Cancer. (Study Code GUT16C3F) Clinical Trial Dispensing Instructions for: A multi-center, open label, randomized phase 2 study of AGS-16C3F vs. aXitinib in metastatic renal
cell carcinoma. Vancouver, British Columbia: BC Cancer; 18 April 2018.
3. Laura Standley. Lead Clinical Study Manager, Astellas Pharma Global Development Inc. Personal communication. 23 January 2019.
4. Novartis Pharmaceuticals Canada Inc. PROLEUKIN® product monograph. Dorval, Quebec; 6 July 2006.
5. McEvoy GK, editor. AHFS 2008 Drug Information. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc. p. 917-925.
6. Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011;365(22):2055-2066.
7. Koreth J, Alyea EP, Cutler C, Ho VT, et al. Clinical Study Protocol: A phase I study of ultra-low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus
host disease. Boston, MA, USA: Dana Farber Cancer Institute; Harvard Medical Centre; 14 Dec 2010.
8. Rui Paiva. Business Unit Director, Transplant and Oncology. Personal communication. 1 June 2009.
9. Bayer HealthCare Pharmaceuticals. MabCampath® Package Insert. Toronto, Ontario; 1 September 2007.
10. Lundin J, Porwit-MacDonald A, Rossmann ED, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment
as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 22 January 2004(18):484-490.
11. Berlex Canada Inc. Campath Drug Information. San Antonio, Texas; undated.
12. Erfa Canada Inc. AMSA PD® injection product monograph. Westmount, Quebec; 16 August 2005.
13. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 6 January 2006.
14. Tanya Leduc. Pharmacist. Acting editor, BC Cancer Agency Cancer Drug Manual. Personal communication. 2 June 2008.
15. Lundbeck Canada Inc. TRISENOX® product monograph. Montreal, Quebec; 6 June 2013.
16. CGF Pharmatec for Jazz Pharmaceuticals France SAS. ERWINASE® product monograph. Montreal, Quebec; 30 August 2016.
17. Hoffmann-La Roche Limited. TECENTRIQ® product monograph. Mississauga, Ontario; 19 September 2019.
18. EMD Serono. BAVENCIO® product monograph. Mississauga, Ontario; 4 May 2018.
19. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 19 September
2007.
20. Celgene Inc. VIDAZA® product monograph. Mississauga, Ontario; 17 May 2012.
21. Kevin Mejo. Medical Information, Celgene Inc. Personal communication. 21 June 2017.
22. Tutino A, Lai M. Cold water reconstitution of Vidaza with subsequent refrigerated storage prolongs drug stability. Eur J Oncol Pharm 2011;5(3-4):24, 25, 34.
23. Celgene Corporation. VIDAZA® full prescribing information. Summit, NJ, USA; December 2012.
24. Dr. Reddy's Laboratories Limited. Azacitidine for injection product monograph. Mississauga, Ontario; 19 April 2017.
25. Merck Canada Inc. OncoTICE® product monograph. Kirkland, Quebec; 29 April 2019.
26. BC Cancer. Provincial Pharmacy Directive Number II-20: Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer; 5 December 2018.
27. Merck & Co. Inc. TICE® BCG full prescribing information. Whitehouse Station, New Jersey, USA; March 2019.
28. Repchinsky C editor. ImmuCyst monograph, Compendium of Pharmaceuticals and Specialties. Ottawa, Ontario; 2005.
29. Spectrum Pharmaceuticals Inc. BELEODAQ® full prescribing information. Irvine, CA, USA; April 2012.
30. Teva Canada Limited. TREANDA® product monograph. Toronto, Ontario; 10 January 2018.
31. Lundbeck Canada Inc. TREANDA® product monograph. Montreal, Quebec; 22 August 2012.
32. Hoffman-La Roche Limited. AVASTIN® product monograph. Mississauga, Ontario; 6 June 2018.
33. Amgen Canada Inc. MVASI® product monograph. Mississauga, Ontario; 5 June 2019.
34. Pfizer Canada ULC. ZIRABEV® product monograph. Kirkland, Quebec; 14 June 2019.
35. Fresenius Kabi Canada Ltd. Bleomycin for injection product monograph. Richmond Hill, Ontario; 1 June 2016.
36. Pfizer Canada Inc. Bleomycin for Injection product monograph. Kirkland, Quebec; 8 August 2017.
37. Amgen Canada Inc. BLINCYTO® product monograph. Mississauga, Ontario; 12 July 2016.
38. Actavis Pharma Company. ACT BORTEZOMIB® Bortezomib for injection product monograph. Mississauga, Ontario; 24 September 2015.
39. Law S, Charbonneau LF, Iazzeta J, et al. Stability of generic formulations of bortezomib 1.0 and 2.5 mg/mL in vials and syringes stored at 4°C and room temperature (23°C). CJHP
Canadian Society of Hospital Pharmacists Professional Practice Conference 2018 Poster Abstracts.Feb 4 - 6, 2018.
40. BC Cancer. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer; 19 September 2007.
41. Apotex Inc. Bortezomib for injection product monograph. Toronto, Ontario; 15 February 2019.
42. Walker SE, Law S, Ma N. (Abstract) Stability of 1.0 and 2.5 mg/mL bortezomib solution in vials and syringes following reconstitution with 0.9% sodium chloride at 4ºC and room
temperature (25ºC). (Apotex brand) Department of Pharmacy, Sunnybrook Health Sciences Centre and Leslie Dan Faculty of Pharmacy, University of Toronto. Toronto, Ontario. 2019
43. Janssen Inc. VELCADE® product monograph. Toronto, Ontario; 20 June 2013.
44. Teva Canada Limited. Bortezomib for injection® product monograph. Toronto, Ontario; 22 January 2015.
45. GMD Distribution Inc. for Seattle Genetics Inc. ADCETRIS® product monograph. Oakville, Ontario; 1 February 2013.
46. Pharmascience Inc. Busulfan for injection product monograph. Montreal, Quebec; 14 June 2018.
47. SteriMax Inc. Busulfan for injection product monograph. Oakville, Ontario; 4 May 2017.
48. Sandoz Canada Inc. Cabazitaxel for injection product monograph. Boucherville, Quebec; 17 December 2019.
49. sanofi-aventis Canada Inc. JEVTANA® product monograph. Laval, Quebec; 7 September 2017.
50. Accord Healthcare Inc. Carboplatin injection® product monograph. Kirkland, Quebec; 15 May 2019.
51. Omega Laboratories Ltd. Carboplatin injection product monograph. Montreal, Quebec; 24 March 2011.
52. Nayla El Zir. Associate, Regulatory Affairs, Omega Laboratories Limited. Personal communication. 12 April 2017.
53. Pfizer Canada ULC. Carboplatin injection product monograph. Kirkland, Quebec; 31 December 2018.
54. Novopharm Limited. Carboplatin Package Insert. Toronto, Canada; Undated.
55. Manjinder S Kang. Regulatory Affairs Drug Information Pharmacist, Novopharm Canada. Personal communication. 14 March 2005.
56. Trissel LA. Handbook on Injectable Drugs. 13th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2005.
57. Repchinsky C editor. Paraplatin-AQ, Compendium of Pharmaceuticals and Specialties. 12th ed. Ottawa, Ontario: Canadian Pharmacists Association; 2004.
58. Amgen Canada Inc. KYPROLIS® product monograph. Mississauga, Ontario; 6 July 2017.
59. Luis Simao. Area Manager, ICU Medical Canada. Personal communication. 11 May 2018.
60. Diane Lord. Medical Information, Amgen Canada Inc. Personal communication. 8 May 2018.
61. Bristol Laboratories of Canada. BiCNU Package Insert. Montreal, Canada; 2002.
62. sanofi-aventis Canada Inc. LIBTAYO® product monograph. Laval, Quebec; 10 April 2019.
63. Regeneron Pharmaceuticals Inc. Pharmacy Manual Protocol R2810-ONC-1676: An open-label, randomized, phase 3 clinical trial of REGN2810 versus therapy of investigator's
choice chemotherapy in recurrent or metastatic platinum cervical cancer. Tarrytown, NY, USA; 26 July 2017 - version 1.0.
64. ImClone LLC (distributed by Eli Lilly Canada Inc). ERBITUX® product monograph. Toronto, Ontario; 10 January 2018.
65. Accord Healthcare Inc. Cisplatin injection product monograph. Kirkland, Quebec; 15 February 2019.
66. Pfizer Canada ULC. Cisplatin injection product monograph. Kirkland, Quebec; 7 December 2018.
67. Sandoz Canada Inc. Cisplatin Injection BP product monograph. Boucherville, Quebec; 13 April 2011.
68. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 19 September
2007.
69. Trissel LA. Handbook on Injectable Drugs. 16th ed. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc; 2011. p. 378.
70. Teva Canada Limited. Cisplatin injection® product monograph. Toronto, Ontario; 6 March 2013.
71. Pharmaceutical Partners of Canada, Inc. Cladribine For Injection product monograph. Richmond Hill, Ontario; 27 November 2008.
72. BC Cancer Agency Lymphoma Tumour Group. (LYCDA) BCCA Protocol Summary for Treatment of Hairy Cell Leukemia with Cladribine. Vancouver, British Columbia: BC Cancer
Agency; 1 February 2007.
73. de Lemos ML, Hamata L. Stability issues of parenteral chemotherapy drugs. J Oncol Pharm Pract Mar 2007;13(1):27-31.
74. Baxter Corporation. PROCYTOX® product monograph. Mississauga, Ontario; 7 September 2012.
75. Baxter Corporation Medical Information. Personal communication. 14 May 2020.
76. Baxter Healthcare Corporation. Cyclophosphamide for injection full prescribing information. Deerfield, Illinois USA; May 2013.
77. Trissel's® 2 Clinical Pharmaceutics Database - Lexicomp Online (database on the Internet). Cyclophosphamide. Wolters Kluwer Clinical Drug Information Inc., undated. Available
at: http://online.lexi.com. Accessed 14 May 2020.
78. Pfizer Canada Inc. Cytarabine Solution for Injection product monograph. Kirkland, Quebec; 3 November 2015.
79. BC Cancer Lymphoma Tumour Group. (LYIT) BC Cancer Protocol Summary for Treatment of Lymphoma using Intrathecal Methotrexate and Cytarabine. Vancouver, British
Columbia: BC Cancer; 1 June 2014.
80. BC Cancer Miscellaneous Origin Tumour Group. (MOIT) BC Cancer Protocol Summary for Solid Tumours using Intrathecal Methotrexate and/or Thiotepa and/or Cytarabine.
Vancouver, British Columbia: BC Cancer; 1 October 2018.
81. BC Cancer. Systemic Therapy Policy and Procedure III-50: Administration of High Alert Medications by the Intrathecal Route via Lumbar Puncture or Ommaya Reservoir.
Vancouver, British Columbia; 1 May 2019.
82. Hospira Healthcare Corporation. Cytarabine Injection® product monograph. Saint-Laurent, Quebec; 25 November 2013.
83. Pharmascience Inc. Cytarabine Solution for Injection product monograph. Montreal, Quebec; 14 February 2017.
84. Abraxis Pharmaceutical Products. Dacarbazine product information package. Schaumburh, IL; December 2006.
85. Trissel L. Handbook on injectable drugs. 13th ed. Bethesda, Maryland: American Society of Health-System Pharmacists; 2005. p. 428-431.
86. Mayne Pharma (Canada) Inc. DACARBAZINE FOR INJECTION product monograph. Montreal, Quebec; 25 July 2003.
87. John Korontzis. Regulatory Affairs Associate,Mayne Pharma Canada. Personal communication: Dacarbazine. 8 February 2005.
88. Caunce, Robert. Quality System Manager, Hospira Australia. Personal communication. 12 March 2008.
89. Pfizer Canada Inc. Dacarbazine for Injection product monograph. Kirkland, Quebec; 31 May 2018.
90. Recordati Rare Diseases Inc. COSMEGEN® product monograph. Lebanon, New Jersey USA; 24 July 2014.
91. Andy Harbrow.Global Medical Services Manager, Primevigilance (for Recordati Rare Diseases Inc.). Personal communication: dactinomycin solutions for infusion. 15 July 2014.
92. Janssen Inc. DARZALEX® product monograph. Toronto, Ontario; 29 June 2016.
93. Erfa Canada Inc. Daunorubicin injection product monograph. Westmount, Quebec; 6 December 2002.
94. Erfa Canada Inc. Material Safety Data Sheet. Montreal, Quebec; 3 October 2007.
95. Henri Knafo MD. Medical Director, Erfa Canada Inc. Personal communication. 14 July 2008.
96. Henri Knafo MD.Medical Director, Erfa Canada Inc. Personal communication. 09 July 2008.
97. Novopharm Limited. Daunorubicin Package Insert. Toronto, Canada; Undated.
98. Ferring Pharmaceuticals. FIRMAGON® product monograph. North York, Ontario; 20 March 2013.
99. Ferring Pharmaceuticals. FIRMAGON® product monograph. North York, Ontario; 06 November 2009.
100. Amgen Canada Inc. XGEVA® product monograph. Mississauga, Ontario; 14 October 2011.
101. Pfizer Canada Inc. ZINECARD® product monograph. Kirkland, Quebec; 12 August 2010.
102. Pfizer Canada Inc. ZINECARD® product monograph. Kirkland, Quebec; 30 March 2015.
103. Unither Biotec Inc. for United Therapeutics Corp. UNITUXIN® product monograph. Magog, Quebec; 28 November 2018.
104. Pfizer Canada Inc. Docetaxel injection product monograph. Kirkland, Quebec; 1 June 2018.
105. Hospira Canada Clinical Support Team, Hospira Canada Healthcare Corporation. Personal communication. 21 March 2011.
106. Josee Lloyd. Senior Clinical Specialist, Hospira Clinical Support Team, Hospira Healthcare Corporation. Personal communication: multidose vials and venting needles. 13 July
2011.
107. Sandoz Canada Inc. Docetaxel injection product monograph. Boucherville, Quebec; 24 January 2018.
108. Bazundama Bazuta Feza Sandrine. Medical Information Intern, Sandoz Canada Inc. Personal communication: in-house vial stability for docetaxel injection. 14 August 2018.
109. Bazundama Bazuta Feza Sandrine. Medical Information Intern, Sandoz Canada Inc. Personal communication: in-house product stability of diluted docetaxel injection. 14 August
2018.
110. sanofi-aventis Canada Inc. TAXOTERE® product monograph. Laval, Quebec; 15 April 2011.
111. Walker SE, Charbonneau F, Law S. Stability of docetaxel solution after dilution in ethanol and storage in vials and after dilution in normal saline and storage in bags. Can J Hosp
Pharm 2007;60(4):231-237.
112. Accord Healthcare Inc. Doxorubicin injection® product monograph. Montreal, Quebec; 9 April 2014.
113. Mayne Pharma (Canada) Inc. Doxorubicin Package Insert. Montreal, QC; Undated.
114. Mayne Pharma (Canada) Inc. Doxorubicin Product Monograph. Montreal, Quebec; 2002.
115. Novopharm Limited. Doxorubicin Product Monograph. Scarborough, Ontario; 8 November 1996.
116. Pfizer Canada Inc. ADRIAMYCIN® injection product monograph. Kirkland, Quebec; 28 August 2007.
117. Janssen Inc. CAELYX® product monograph. Toronto, Ontario; 10 October 2013.
118. AstraZeneca Canada Inc. IMFINZI® product monograph. Mississauga, Ontario; 4 July 2019.
119. Novopharm. Epirubicin for Injection product monograph. Toronto, Ontario; 16 March 2009.
120. Pharmaceutical Partners of Canada, Inc. Epirubicin Hydrochloride Injection product monograph. Richmond Hill, Ontario; 6 July 2010.
121. Pharmacia Canada Inc. Pharmorubicin PFS Package Insert. Mississauga, Ontario; May 2003.
122. Trissel LA. Handbook on Injectable Drugs. 12th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2003.
123. BC Cancer Agency Lymphoma Tumour Group. (ULYEPOCHR) Interim BCCA Protocol Summary for Treatment of Lymphoma with Dose-Adjusted Etoposide, DOXOrubicin,
VinCRIStine, Cyclophosphamide, PredniSONE, and riTUXimab (LYEPOCHR) with Intrathecal Methotrexate. Vancouver, British Columbia: BC Cancer Agency; 1 July 2015.
124. Barry Goldspiel. NIH Clinical Centre. Personal communication: EPOCHR. 14 April 2015.
125. Wolfe JL, Thoma LA, Du C, et al. Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide in 0.9% sodium chloride injection. Am J Health-Syst
Pharm 1999;56:985-989.
126. Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med 2013;369:1915-1925.
127. Eisai Limited. HALAVEN® product monograph. Mississauga, Ontario; 17 January 2013.
128. Sandoz Canada Inc. Etoposide injection product monograph. Kirkland, Quebec; 27 February 2012.
129. BC Cancer Agency. Provincial Pharmacy Directive III-50-04: Management of Particulate During Sterile Preparation. Vancouver, British Columbia: BC Cancer Agency; 9 July
2014.
130. Novopharm Limited. Etoposide Product Monograph. Toronto, Ontario; 2000.
131. Lepage R, Walker S, Godin J. Stability and compatibility of etoposide in normal saline. Canadian Journal of Hospital Pharmacy December 2000;53(5):338-345.
132. The United States Pharmacopeial Convention, Inc. General Chapter 797: Pharmaceutical compounding - sterile preparations. USP 27-NF 22. Rockville, Maryland: The United
States Pharmacopeial Convention, Inc.; 2003.
133. Angie Chan. Drug Information Pharmacist, Novopharm. Personal communication. 29 September 2006.
134. Bristol-Myers Squibb Company. ETOPOPHOS® product monograph. Princeton, New Jersey, USA; March 2011.
135. Joseph Atallah. Interim County Medical Director. Personal communication re: new Canadian distributor for ETOPOPHOS®. Bristol-Myers Squibb Canada.; 15 November 2019.
136. George Gafrey. VP Business Development. Personal communication re: new Canadian distributor for ETOPOPHOS®. Xediton Pharmaceuticals Inc.; 27 November 2019.
137. Bristol-Myers Squibb Company. ETOPOPHOS® product monograph. Princeton, New Jersey, USA; September 2013.
138. Amgen Canada Inc. NEUPOGEN® product monograph. MIssissauga, Ontario; 21 March 2014.
139. Amgen Medical Information. Amgen Canada Inc. Personal communication. 8 July 2014.
140. Trissel LA. Handbook on Injectable Drugs. 13th ed. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc; 2005. p. 648-655.
141. Berlex Canada Inc. Fludara Package Insert. Lachine, Quebec; December 1998.
142. Trissel's™2 Clinical Pharmaceutics Database (Parenteral Compatibility) [database on the internet]. Fludarabine. Thomson MICROMEDEX®, Available at:
http://www.micromedex.com/. Accessed 14 September, 2007.
143. Novopharm Limited. Fludarabine product information package. Toronto, Ontario; 21 June 2007.
144. Accord Healthcare Inc. Fluorouracil injection® product monograph. Kirkland, Quebec; 30 September 2013.
145. Charles Vachon. Quality and Regulatory Affairs, Accord Healthcare Inc. Personal communication. 29 September 2016.
146. John Korontzis. Regulatory Affairs Associate,Mayne Pharma Canada. Personal communication: Fluorouracil. February 16, 2005.
147. Pfizer Canada Inc. Fluorouracil injection product monograph. Kirkland, Quebec; 17 April 2018.
148. Trissel LA. Fluorouracil. Handbook on Injectable Drugs: 13th ed. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc; 2005. p. 672-681.
149. Stiles ML, Allen Jr LV, Tu YH. Stability of fluorouracil administered through four portable infusion pumps. American Journal of Hospital Pharmacy 1989;46(10):2036-2040.
150. BC Cancer Agency Experimental Therapeutics. Physicochemical stability analysis of fluorouracil products in final chemotherapeutic preparations.Vancouver, BC. 19 August
2011;Study number 50009:1-43.
151. Sandoz Canada Inc. Fluorouracil Injection product monograph. Boucherville, Quebec; 3 April 2012.
152. Alexandre Dussault. Drug Information & Pharmacovigilance Coordinator, Sandoz Canada Inc. Personal communication. 19 November 2015.
153. Accord Healthcare Inc. Gemcitabine injection® product monograph. Kirkland, Quebec; 29 September 2014.
154. Astron Research LTD. UK. Gemcitabine for Injection (STBRG/ACGEM/01) Stability Study Report (Dilution Study) 2001.
155. Purvi Agrawal BScPharm. Regulatory Affairs Manager, Accord Healthcare Inc. Personal communication. 07 September 2012.
156. Pfizer Canada Inc. Gemcitabine Injection (ready to use solution) product monograph. Kirkland, Quebec; 25 October 2018.
157. Pfizer Canada Inc. Gemcitabine Injection (ready to use solution) product monograph. Kirkland, Quebec; 24 August 2017.
158. Sandoz Canada Inc. Gemcitabine hydrochloride solution for injection product monograph. Boucherville, Quebec; 14 August 2014.
159. Pfizer Canada Inc. IDAMYCIN® product monograph. Kirkland, Quebec; 19 February 2009.
160. Pharmaceutical Partners of Canada, Inc. IDARUBICIN HYDROCHLORIDE INJECTION® product monograph. Richmond Hill, Ontario; 12 November 2009.
161. Baxter Corporation. IFEX® product monograph. Mississauga, Ontario; 5 April 2012.
162. Pharmaceutical Partners of Canada, Inc. Ifosfamide for Injection product monograph. Richmond Hill, Ontario; 17 January 2008.
163. sanofi-aventis Canada. Iniparib (BSI-201;SAR240550) Special Access Program Guidance for the Physician. Laval, Quebec; 15December2010.
164. Pfizer Canada Inc. BESPONSA® product monograph. Kirkland, Quebec; 15 March 2018.
165. Pfizer Medical Information. Pfizer Canada Inc. Personal communication. 26 November 2018.
166. Merck Canada Inc. INTRON A® product monograph. Kirkland, Quebec; 13 March 2015.
167. Edward Kavalec BSc(Pharm). Medical Services Specialist. Merck Canada Inc. Medical Information. Personal communication. 1 April 2015.
168. Bristol Myers Squibb Canada. YERVOY® product monograph. Montreal, Quebec; 1 February 2012.
169. Accord Healthcare Inc. Irinotecan injection® product monograph. Kirkland, Quebec; 6 May 2014.
170. Pfizer Canada Inc. Irinotecan hydrochloride trihydrate for injection product monograph. Kirkland, Quebec; 6 March 2019.
171. Pfizer Canada Inc. Irinotecan hydrochloride injection product monograph. Kirkland, Quebec; 8 March 2019.
172. Servier Canada Inc. ONIVYDE® product monograph. Laval, Quebec; 4 January 2019.
173. Bristol-Myers Squibb. IXEMPRA® product monograph. Princeton, New Jersey; 01 October 2007.
174. The United States Pharmacopeia (USP). General Chapter 797: Pharmaceutical compounding - sterile preparations. USP 27-NF 22. Rockville, Maryland: The United States
Pharmacopeial Convention, Inc.; 2004.
175. Kastango ES. The ASHP discussion guide for compounding sterile preparations. Bethesda (MD): American Society of Health-System Pharmacists, Inc.; 2004. p. 5.

Chemo Stability Chart - AtoK

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Chemo Stability Chart - AtoK

Uploaded by

Copyright:

Available Formats

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART

transfer 1.5mL from

record time of if a closed system

swirl gently; do NOT

do NOT use D5W

swirl gently; avoid

Let sit for 5

(e.g., 50-1000 mL*

CIVI: ambulatory complete within 8

(e.g., 50-1000 mL*

CIVI: ambulatory complete within

CIVI: ambulatory complete within

vial contents under

do NOT use BWI to

Interferon Alfa -2b

Interferon Alfa -2b

BWI = bacteriostatic water for injection

You might also like